$PCVX
Vaxcyte, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023059395 Filed on November 06, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.53M $15.61M $23.33M
YoY Change -24.89% -21.38% 95.71%
% of Gross Profit
Research & Development $104.2M $97.42M $40.24M
YoY Change 158.8% 104.33% 124.54%
% of Gross Profit
Depreciation & Amortization $888.0K $810.0K $702.0K
YoY Change 26.5% 18.42% 52.94%
% of Gross Profit
Operating Expenses $121.7M $113.0M $63.58M
YoY Change 91.38% 92.95% 113.02%
Operating Profit -$113.0M
YoY Change 92.95%
Interest Expense $15.87M $0.00 $7.642M
YoY Change 107.66% 1937.87%
% of Operating Profit
Other Income/Expense, Net $6.000K $20.36M $925.0K
YoY Change -99.35% 2985.15% 1.87%
Pretax Income -$180.8M -$92.66M -$78.05M
YoY Change 131.65% 59.99% 173.26%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$180.8M -$92.66M -$78.05M
YoY Change 131.65% 59.99% 173.26%
Net Earnings / Revenue
Basic Earnings Per Share -$0.91
Diluted Earnings Per Share -$1.76 -$0.91 -$0.99
COMMON SHARES
Basic Shares Outstanding 95.15M 93.85M 78.98M
Diluted Shares Outstanding 101.7M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.080B $1.266B $931.4M
YoY Change 15.98% 249.42% 278.65%
Cash & Equivalents $397.5M $545.1M $834.7M
Short-Term Investments $682.8M $720.6M $96.72M
Other Short-Term Assets $2.105M $1.299M $11.18M
YoY Change -81.17% -82.76% 7.72%
Inventory
Prepaid Expenses $6.159M $15.34M $5.312M
Receivables
Other Receivables
Total Short-Term Assets $1.096B $1.295B $942.6M
YoY Change 16.27% 250.35% 267.69%
LONG-TERM ASSETS
Property, Plant & Equipment $79.63M $11.43M $10.36M
YoY Change 668.59% 14.92% 30.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $162.7M $168.6M $26.55M
YoY Change 512.73% 4139.38% -2.09%
Other Assets $37.56M $3.192M $4.555M
YoY Change 724.63% -30.97% 11.4%
Total Long-Term Assets $312.0M $200.6M $63.62M
YoY Change 390.33% 374.22% -6.42%
TOTAL ASSETS
Total Short-Term Assets $1.096B $1.295B $942.6M
Total Long-Term Assets $312.0M $200.6M $63.62M
Total Assets $1.408B $1.496B $1.006B
YoY Change 39.93% 263.06% 210.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.59M $15.70M $9.795M
YoY Change 48.92% 186.31% 44.94%
Accrued Expenses $59.82M $15.02M $15.38M
YoY Change 289.04% 9.82% 74.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $145.3M $85.56M $40.53M
YoY Change 258.64% 117.65% 41.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $2.000K $9.000K
YoY Change -100.0% -97.75% -90.63%
Total Long-Term Liabilities $0.00 $2.000K $9.000K
YoY Change -100.0% -97.75% -90.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $145.3M $85.56M $40.53M
Total Long-Term Liabilities $0.00 $2.000K $9.000K
Total Liabilities $167.4M $93.34M $52.57M
YoY Change 218.56% 76.94% 30.37%
SHAREHOLDERS EQUITY
Retained Earnings -$924.4M -$743.6M -$522.1M
YoY Change 77.04% 67.45% 74.83%
Common Stock $2.165B $2.149B $1.476B
YoY Change 46.65% 167.22% 153.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.240B $1.403B $953.6M
YoY Change
Total Liabilities & Shareholders Equity $1.408B $1.496B $1.006B
YoY Change 39.93% 263.06% 210.23%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4
OPERATING ACTIVITIES
Net Income -$180.8M -$92.66M -$78.05M
YoY Change 131.65% 59.99% 173.26%
Depreciation, Depletion And Amortization $888.0K $810.0K $702.0K
YoY Change 26.5% 18.42% 52.94%
Cash From Operating Activities -$128.8M -$57.55M -$65.22M
YoY Change 97.5% 49.29% 27.65%
INVESTING ACTIVITIES
Capital Expenditures $57.07M $7.340M $1.147M
YoY Change 4875.5% -970.7% -183.0%
Acquisitions
YoY Change
Other Investing Activities $43.14M $29.62M -$34.80M
YoY Change -223.96% -16.68% -2477.39%
Cash From Investing Activities -$13.93M $22.28M -$35.95M
YoY Change -61.27% -35.8% -43943.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.735M 48.55M 656.6M
YoY Change -99.58% 10.3% 7400.95%
NET CHANGE
Cash From Operating Activities -128.8M -57.55M -65.22M
Cash From Investing Activities -13.93M 22.28M -35.95M
Cash From Financing Activities 2.735M 48.55M 656.6M
Net Change In Cash -140.0M 13.28M 555.5M
YoY Change -125.2% -66.94% -1414.48%
FREE CASH FLOW
Cash From Operating Activities -$128.8M -$57.55M -$65.22M
Capital Expenditures $57.07M $7.340M $1.147M
Free Cash Flow -$185.9M -$64.89M -$66.37M
YoY Change 180.07% 72.1% 33.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001649094
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39323
dei Entity Registrant Name
EntityRegistrantName
VAXCYTE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4233385
dei Entity Address Address Line1
EntityAddressAddressLine1
825 Industrial Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
San Carlos
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94070
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
837-0111
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
PCVX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
95153909
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
545134000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
834657000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
720550000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
96719000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
29750000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11179000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
1295434000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
942555000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11431000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10360000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16333000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21288000
CY2023Q3 us-gaap Long Term Investments
LongTermInvestments
168564000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
26549000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1103000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
871000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3192000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4555000
CY2023Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
200623000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
63623000
CY2023Q3 us-gaap Assets
Assets
1496057000
CY2022Q4 us-gaap Assets
Assets
1006178000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10898000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43174000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
15704000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9795000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6925000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1180000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27858000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
113026000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
58577000
CY2023Q3 pcvx Accrued Manufacturing Expenses
AccruedManufacturingExpenses
41880000
CY2022Q4 pcvx Accrued Manufacturing Expenses
AccruedManufacturingExpenses
8265000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15021000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15375000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6028000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5910000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
85558000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40525000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7781000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12031000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9000
CY2023Q3 us-gaap Liabilities
Liabilities
93341000
CY2022Q4 us-gaap Liabilities
Liabilities
52565000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95099101
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95099101
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79470670
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79470670
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
98000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
82000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2148499000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1476018000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2290000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-361000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-743591000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-522126000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1402716000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
953613000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1496057000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1006178000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97421000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47679000
us-gaap Operating Expenses
OperatingExpenses
271365000
us-gaap Operating Expenses
OperatingExpenses
145683000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
228191000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
117825000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15605000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-113026000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-58577000
us-gaap Operating Income Loss
OperatingIncomeLoss
-271365000
us-gaap Operating Income Loss
OperatingIncomeLoss
-145683000
CY2023Q3 us-gaap Interest Expense
InterestExpense
0
CY2022Q3 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
2000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
18495000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1190000
us-gaap Investment Income Interest
InvestmentIncomeInterest
45339000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1723000
CY2023Q3 pcvx Grant Income
GrantIncome
1640000
CY2022Q3 pcvx Grant Income
GrantIncome
157000
pcvx Grant Income
GrantIncome
4759000
pcvx Grant Income
GrantIncome
1006000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
227000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-687000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-198000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2479000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20362000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
660000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
49900000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
248000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-92664000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-57917000
us-gaap Net Income Loss
NetIncomeLoss
-221465000
us-gaap Net Income Loss
NetIncomeLoss
-145435000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.42
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101668655
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101668655
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61989347
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61989347
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95367751
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95367751
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60166583
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60166583
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-92664000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-57917000
us-gaap Net Income Loss
NetIncomeLoss
-221465000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1757000
CY2022Q3 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
2000
CY2022Q3 pcvx Release Of Restricted Stock Units Value
ReleaseOfRestrictedStockUnitsValue
861000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6648000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
247000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-57917000
us-gaap Net Income Loss
NetIncomeLoss
-145435000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
231000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
247000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-1929000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-416000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-92433000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57670000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-223394000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-145851000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
953613000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
502000
CY2023Q1 pcvx Release Of Restricted Stock Units Value
ReleaseOfRestrictedStockUnitsValue
727000
CY2023Q1 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
2000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9648000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
408000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-60462000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
944771000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
884000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1017000
CY2023Q2 pcvx Release Of Restricted Stock Units Value
ReleaseOfRestrictedStockUnitsValue
214000
CY2023Q2 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
2000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12544000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2568000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-68339000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1433376000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2156000
CY2023Q3 pcvx Release Of Restricted Stock Units Value
ReleaseOfRestrictedStockUnitsValue
2605000
CY2023Q3 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
2000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13220000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
231000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-92664000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1402716000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
284018000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
282000
CY2022Q1 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
2000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4099000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-592000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-38986000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
359543000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
324000
CY2022Q2 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
2000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
550000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5894000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-71000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-48532000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
366500000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
359311000
us-gaap Profit Loss
ProfitLoss
-221465000
us-gaap Profit Loss
ProfitLoss
-145435000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2268000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1875000
us-gaap Share Based Compensation
ShareBasedCompensation
35412000
us-gaap Share Based Compensation
ShareBasedCompensation
16641000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4955000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5021000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
32406000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-228000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-44000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
213000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2431000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2852000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1363000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
534000
pcvx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
4132000
pcvx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2991000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4746000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-575000
pcvx Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
5745000
pcvx Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-4000
pcvx Increase Decrease In Accrued Manufacturing Expenses
IncreaseDecreaseInAccruedManufacturingExpenses
33614000
pcvx Increase Decrease In Accrued Manufacturing Expenses
IncreaseDecreaseInAccruedManufacturingExpenses
5830000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-511000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5477000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-167980000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-105376000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10808000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4701000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1126286000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
31460000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
368919000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
136191000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
8790000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
10500000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-759385000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
110537000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3541000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2363000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
90787000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
95238000
pcvx Proceeds From Issuance Of Common Stock From Follow On Offering Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockFromFollowOnOfferingNetOfIssuanceCosts
545279000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1177000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
13809000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1900000
pcvx Proceeds From Issuance Of Common Stock From Follow On Offering Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockFromFollowOnOfferingNetOfIssuanceCosts
107624000
pcvx Release Of Restricted Stock Units Value
ReleaseOfRestrictedStockUnitsValue
3546000
pcvx Release Of Restricted Stock Units Value
ReleaseOfRestrictedStockUnitsValue
861000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1017000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
550000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
637078000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
204914000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
996000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-659000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-289291000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
209416000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
835528000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69856000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
546237000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
279272000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
2000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
433000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
141000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the valuation of deferred tax assets and income taxes. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
545134000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
834657000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
1103000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
871000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
546237000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
835528000
pcvx Number Of Finance Lease
NumberOfFinanceLease
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash, cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally-insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the condensed balance sheets. For example, on March 10, 2023, the California Department of Financial Protection and Innovation took control of Silicon Valley Bank (“SVB”) and appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver. While SVB was our primary bank at the time, we maintained banking relationships with other major banks. The substantial majority of funds we held at SVB, which included cash, cash equivalents and investments, were held in custodial accounts of a third-party institution for which SVB Asset Management was the advisor (“SVB Custodial Accounts”). On March 12, 2023, the FDIC confirmed that depositors of SVB would have access to all of their money and, as a result, we regained access to all of our funds deposited with SVB. The FDIC subsequently transferred SVB’s deposits and loans to a newly created bridge bank, named Silicon Valley Bridge Bank, N.A. (“Silicon Valley Bridge Bank”). On March 26, 2023, the FDIC announced that First Citizens Bank &amp; Trust Company (“First Citizens Bank”) had agreed to purchase and assume all deposits and loans of Silicon Valley Bridge Bank. Management believes that we are not exposed to significant credit risk as our deposits are held at First Citizens Bank, and our investments are held under separate financial institution custodial accounts, each of which management continues to believe to be of high credit quality. We have not experienced any losses on these deposits or investments as a result of this market event. While we were able to recover all deposited amounts from SVB, and continue to have access to all investments held in the SVB Custodial Accounts, there can be no assurance that our current or future banks will not face similar risks as SVB or that we will be able to recover in full our deposits in the event of similar closures. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.</span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to supplier concentration risk from our suppliers. Although we are working to establish secondary sources of supply, we currently source several of our critical raw materials from single-source suppliers. We also use one contract manufacturing organization (“CMO”), Lonza Ltd. (“Lonza”), to handle most of our manufacturing activities for our VAX-24 and VAX-31 programs. If we were to experience disruptions in raw materials supplied by our suppliers, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and immunogenicity or efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the “Risk Factors” section of this Quarterly Report on Form 10-Q.</span></p>
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
720550000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
168564000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
889114000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15335000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5312000
CY2023Q3 pcvx Purchased Equipment Deposits Current
PurchasedEquipmentDepositsCurrent
7792000
CY2022Q4 pcvx Purchased Equipment Deposits Current
PurchasedEquipmentDepositsCurrent
0
CY2023Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
3438000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
2848000
CY2023Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1886000
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1029000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1299000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1990000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
29750000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11179000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19815000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16477000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8384000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6117000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11431000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10360000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1900000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7022000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
14986000
CY2023Q3 pcvx Clinical Studies
ClinicalStudies
476000
CY2022Q4 pcvx Clinical Studies
ClinicalStudies
1518000
CY2023Q3 pcvx Other Research And Development Liabilities Current
OtherResearchAndDevelopmentLiabilitiesCurrent
12052000
CY2022Q4 pcvx Other Research And Development Liabilities Current
OtherResearchAndDevelopmentLiabilitiesCurrent
12446000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2493000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1411000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15021000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15375000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1671000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1631000
us-gaap Operating Lease Payments
OperatingLeasePayments
5013000
us-gaap Operating Lease Payments
OperatingLeasePayments
3743000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y14D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y14D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
CY2023Q3 pcvx Lessee Operating Lease Liability Payments Net Of Lease Incentives Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear
1114000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6850000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
5800000
us-gaap Operating Lease Expense
OperatingLeaseExpense
6000000
CY2021Q2 pcvx Development And Manufacturing Services Agreement Payments In Equity
DevelopmentAndManufacturingServicesAgreementPaymentsInEquity
10000000
CY2023Q3 pcvx Non Cancelable Purchase Commitments Due Within One Year
NonCancelablePurchaseCommitmentsDueWithinOneYear
46324000
CY2023Q3 pcvx Non Cancelable Purchase Commitments Due In Second Year
NonCancelablePurchaseCommitmentsDueInSecondYear
77450000
CY2023Q3 pcvx Non Cancelable Purchase Commitments Due In Third Year
NonCancelablePurchaseCommitmentsDueInThirdYear
1856000
CY2023Q3 pcvx Non Cancelable Purchase Commitments Due In Four Year
NonCancelablePurchaseCommitmentsDueInFourYear
1061000
CY2023Q3 pcvx Non Cancelable Purchase Commitments
NonCancelablePurchaseCommitments
126691000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95099101
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95099101
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79470670
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79470670
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
36710
CY2022Q1 pcvx Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
0.001
CY2022Q4 pcvx Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
0.001
CY2023Q2 pcvx Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
0.001
CY2022Q4 pcvx Increase Or Decrease Of Pre Funded Warrant Percentage Not Exceed
IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed
0.1999
CY2022Q1 pcvx Increase Or Decrease Of Pre Funded Warrant Percentage Not Exceed
IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed
0.1999
CY2023Q2 pcvx Increase Or Decrease Of Pre Funded Warrant Percentage Not Exceed
IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed
0.1999
CY2023Q3 pcvx Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
0
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
CY2023Q3 pcvx Early Exercised Stock Options
EarlyExercisedStockOptions
927
CY2022Q4 pcvx Early Exercised Stock Options
EarlyExercisedStockOptions
3705
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
36710
pcvx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod
190378
CY2023Q3 pcvx Number Of Options Exercised Excludes Options Exercised From Npln
NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln
144818
CY2022Q3 pcvx Number Of Options Exercised Excludes Options Exercised From Npln
NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln
222358
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
14.89
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.9
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
30.65
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.01
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5000000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4000000
pcvx Number Of Options Exercised Excludes Options Exercised From Npln
NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln
315733
pcvx Number Of Options Exercised Excludes Options Exercised From Npln
NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln
390467
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.33
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
28.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7400000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
456766
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
26700
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
500953
pcvx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted
43930
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
216636
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
30640
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
40665
pcvx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled
40190
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
700418
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
37020.00
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.713
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.721
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.804
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.806
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.713
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.781
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.812
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M24D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.042
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.044
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.027
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.044
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.04
CY2023Q3 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
300000
CY2022Q3 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
200000
us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
1000000
us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
500000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
92664000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-57917000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
221465000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-145435000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101668655
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101668655
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61989347
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61989347
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95367751
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95367751
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60166583
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60166583
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.42
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10098299
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8181026
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
pcvx-20230930_cal.xml Edgar Link unprocessable
pcvx-20230930_def.xml Edgar Link unprocessable
0000950170-23-059395-index-headers.html Edgar Link pending
0000950170-23-059395-index.html Edgar Link pending
0000950170-23-059395.txt Edgar Link pending
0000950170-23-059395-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img64561679_0.jpg Edgar Link pending
img64561679_1.jpg Edgar Link pending
img64561679_10.jpg Edgar Link pending
img64561679_11.jpg Edgar Link pending
img64561679_12.jpg Edgar Link pending
img64561679_13.jpg Edgar Link pending
img64561679_14.jpg Edgar Link pending
img64561679_15.jpg Edgar Link pending
img64561679_16.jpg Edgar Link pending
img64561679_17.jpg Edgar Link pending
img64561679_18.jpg Edgar Link pending
img64561679_19.jpg Edgar Link pending
img64561679_2.jpg Edgar Link pending
img64561679_20.jpg Edgar Link pending
img64561679_21.jpg Edgar Link pending
img64561679_22.jpg Edgar Link pending
img64561679_23.jpg Edgar Link pending
img64561679_24.jpg Edgar Link pending
img64561679_25.jpg Edgar Link pending
img64561679_26.jpg Edgar Link pending
img64561679_27.jpg Edgar Link pending
img64561679_28.jpg Edgar Link pending
img64561679_29.jpg Edgar Link pending
img64561679_3.jpg Edgar Link pending
img64561679_30.jpg Edgar Link pending
img64561679_31.jpg Edgar Link pending
img64561679_32.jpg Edgar Link pending
img64561679_33.jpg Edgar Link pending
img64561679_34.jpg Edgar Link pending
img64561679_35.jpg Edgar Link pending
img64561679_36.jpg Edgar Link pending
img64561679_37.jpg Edgar Link pending
img64561679_38.jpg Edgar Link pending
img64561679_39.jpg Edgar Link pending
img64561679_4.jpg Edgar Link pending
img64561679_40.jpg Edgar Link pending
img64561679_41.jpg Edgar Link pending
img64561679_42.jpg Edgar Link pending
img64561679_43.jpg Edgar Link pending
img64561679_44.jpg Edgar Link pending
img64561679_45.jpg Edgar Link pending
img64561679_46.jpg Edgar Link pending
img64561679_47.jpg Edgar Link pending
img64561679_48.jpg Edgar Link pending
img64561679_49.jpg Edgar Link pending
img64561679_5.jpg Edgar Link pending
img64561679_50.jpg Edgar Link pending
img64561679_51.jpg Edgar Link pending
img64561679_52.jpg Edgar Link pending
img64561679_53.jpg Edgar Link pending
img64561679_54.jpg Edgar Link pending
img64561679_55.jpg Edgar Link pending
img64561679_6.jpg Edgar Link pending
img64561679_7.jpg Edgar Link pending
img64561679_8.jpg Edgar Link pending
img64561679_9.jpg Edgar Link pending
img65485200_0.jpg Edgar Link pending
img65485200_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pcvx-20230930.htm Edgar Link pending
pcvx-20230930.xsd Edgar Link pending
pcvx-ex10_1.htm Edgar Link pending
pcvx-ex10_2.htm Edgar Link pending
pcvx-ex10_3.htm Edgar Link pending
pcvx-ex31_1.htm Edgar Link pending
pcvx-ex31_2.htm Edgar Link pending
pcvx-ex32_1.htm Edgar Link pending
pcvx-ex3_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
pcvx-20230930_lab.xml Edgar Link unprocessable
pcvx-20230930_pre.xml Edgar Link unprocessable
pcvx-20230930_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending